quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 27, 2025

Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035

View original at globenewswire.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 Ottawa, Nov…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • IV route accounts for 90% of ADC administration in 2024

    80% confidence

  • Asia-Pacific is the fastest growing ADC market region

    80% confidence

  • Generic/biosimilar ADCs are the fastest growing drug type segment

    80% confidence

  • Global antitumor ADC drugs market will grow from $8.33B in 2026 to $24.75B in 2035 at 12.86% CAGR

    80% confidence

  • Hospital pharmacies and oncology centers represent 70% of ADC distribution in 2024

    80% confidence

  • North America holds 55% revenue share of ADC market in 2024

    80% confidence

  • Cleavable linkers represent 60% of ADC linker market share in 2024

    80% confidence

  • Cytotoxic payloads represent 70% of ADC payload market share in 2024

    80% confidence

  • Solid tumors represent the fastest growing therapeutic area for ADCs

    80% confidence

  • Branded ADC drugs represent 75% market share in 2024

    80% confidence

  • Hematologic cancers represent 35% of ADC therapeutic area market in 2024

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Antitumor ADC Drugs Market Forecast Shows Strong 12.86% CAGR Through 2035 — Source | Via News | pt.VIA.NEWS